Back to top
more

Allergan plc (AGN)

(Delayed Data from NYSE)

$145.81 USD

145.81
1,518,334

+1.56 (1.08%)

Updated May 3, 2019 04:01 PM ET

After-Market: $145.88 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Amgen's Repatha Gains CHMP Nod to Include Outcomes Data

by Zacks Equity Research

Amgen (AMGN) gets CHMP's positive opinion to incorporate a new indication into the European label of its PCSK9 inhibitor, Repatha.

    AbbVie's Uterine Fibroids Candidate Succeeds in Phase III

    by Zacks Equity Research

    AbbVie (ABBV) and partner Neurocrine Biosciences announce that the second of the two pivotal phase III studies evaluating elagolix, met the primary endpoint for treating women with uterine fibroids.

      The Zacks Analyst Blog Highlights: Lockheed Martin, Allergan, Barclays, Constellation Brands and Southwest Airlines

      by Zacks Equity Research

      The Zacks Analyst Blog Highlights: Lockheed Martin, Allergan, Barclays, Constellation Brands and Southwest Airlines

        Why Is Allergan (AGN) Down 10.1% Since its Last Earnings Report?

        by Zacks Equity Research

        Allergan (AGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

          Aerie's (AERI) Q4 Loss Wider on Higher Operating Expenses

          by Zacks Equity Research

          Aerie (AERI) incurs a wider-than-expected loss in the fourth quarter due to higher operating expenses.

            Abbvie's Uterine Fibrosis Candidate Meets Goal in Study

            by Zacks Equity Research

            AbbVie's (ABBV) phase III study of its late stage candidate elagolix meets its primary endpoint in women with uterine fibroids.

              Teva's Problems Continue to Mount With No Relief in Sight

              by Zacks Equity Research

              Teva (TEVA) faces significant challenges including rapid erosion in sales of Copaxone and pricing erosion in the U.S. generics business.

                Ironwood (IRWD) Beats Estimates in Q4 Earnings, Stock Up

                by Zacks Equity Research

                Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the fourth quarter. Demand for Linzess continues to rise.

                  Teva (TEVA) Q4 Earnings Top, Stock Tanks on Weak 2018 View

                  by Zacks Equity Research

                  Teva's (TEVA) fourth-quarter earnings and sales beat expectations. However, the 2018 sales and earnings outlook falls short of consensus estimate.

                    Allergan (AGN) Q4 Earnings Beat on Increase in Botox Sales

                    by Zacks Equity Research

                    Allergan (AGN) beats expectations for both earnings and revenues in Q4. A phase III study evaluating Allergan's migraine candidate, ubrogepant meets its co-primary endpoints.

                      Allergan (AGN) Beats Q4 Earnings & Sales, Stock Up

                      by Zacks Equity Research

                      Allergan (AGN) beats expectations for both earnings and revenues in Q4. A phase III study evaluating Allergan's migraine candidate, ubrogepant meets its co-primary endpoints.

                        Teva Completes Sale of Women's Health Segment for $703M

                        by Zacks Equity Research

                        Teva Pharmaceutical (TEVA) sells woman health specialty products for cash consideration of $703 million.

                          Allergan's Anti-Infective Drug Avycaz Receives Third FDA Nod

                          by Zacks Equity Research

                          The FDA's label expansion approval for Allergan's (AGN) Avycaz marks its third therapeutic indication nod for the anti-infective drug in the United States.

                            Allergan (AGN) to Report Q4 Earnings: What's in the Cards?

                            by Zacks Equity Research

                            While Allergan's (AGN) Q4 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products will hurt sales.

                              Amgen's Migraine Drug Hits Primary Endpoint in Phase IIIb

                              by Zacks Equity Research

                              Amgen's (AMGN) antibody Aimovig meets all primary and secondary endpoints in a phase IIIb study on patients with episodic migraine, who have failed multiple prior preventive treatments.

                                Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies

                                by Zacks Equity Research

                                Teva's (TEVA) two phase III studies evaluating the subcutaneous formulation of its asthma injection, Cinqair (reslizumab) fail to meet primary endpoints.

                                  Amgen/Allergan's Avastin Biosimilar Secures EU Approval

                                  by Zacks Equity Research

                                  Amgen (AMGN) and Allergan's Mvasi - a biosimilar version of Roche's cancer drug, Avastin - gets marketing approval in the EU.

                                    Cancer Space Update: Label Expansions, Data Readouts in Focus

                                    by Zacks Equity Research

                                    This week the cancer space was abuzz with news of label expansion of Kyprolis, Lynparza and Kymriah and positive data readouts for Cabometyx and Keytruda.

                                      Teva's Trisenox Gets FDA Approval as First-Line Treatment

                                      by Zacks Equity Research

                                      Teva Pharmaceutical (TEVA) receives approval from the FDA for label expansion of its leukemia drug, Trisenox, in first-line setting.

                                        Will Amgen (AMGN) Continue to Tread Growth Path This Year?

                                        by Zacks Equity Research

                                        Amgen (AMGN) stock outperformed the industry in 2017. We will have to wait and see if it can keep the momentum alive in 2018.

                                          Big Pharma CEOs Speak About Impact of Tax Reform on M&A

                                          by Zacks Equity Research

                                          This week, senior executives of some large drug companies discussed the impact of tax reform on mergers and acquisition and their plans to use the excess cash at the JP Morgan HealthCare conference.

                                            Allergan's (AGN) Sales Guidance for 2018 Lower Than Expected

                                            by Zacks Equity Research

                                            Allergan (AGN) announces weaker-than-expected sales outlook for 2018. A generic version of Restasis is expected to be launched in Q2.

                                              Key Biosimilar Approvals in 2017: Progress Report

                                              by Zacks Equity Research

                                              The biosimilar space was much in focus as the FDA approved a few biosimilars for key blockbuster drugs. We expect investor focus on the same in 2018 as well.

                                                Allergan to Cut Jobs Amid Loss of Exclusivity for Key Drugs

                                                by Zacks Equity Research

                                                Allergan (AGN) is laying off over 1,000 employees as part of a cost-cutting and restructuring program as it faces potential loss of exclusivity for some of its key products in 2018.

                                                  Valeant (VRX) to Settle Allergan Litigation for $290 Million

                                                  by Zacks Equity Research

                                                  Valeant (VRX) and Pershing Square decided to resolve the claims of the long standing Allergan lawsuit for $290 million. Valeant will now pay 33% of the costs, down from the previous agreement of 60%.